null
US
Iniciar Sesión
Regístrate Gratis
Registro
Hemos detectado que no tienes habilitado Javascript en tu navegador. La naturaleza dinámica de nuestro sitio requiere que Javascript esté habilitado para un funcionamiento adecuado. Por favor lee nuestros
términos y condiciones
para más información.
Siguiente
Copiar y Editar
¡Debes iniciar sesión para completar esta acción!
Regístrate gratis
46581
Atherosclerosis
Descripción
Mapa Mental sobre Atherosclerosis, creado por tanitia.dooley el 15/04/2013.
Mapa Mental por
tanitia.dooley
, actualizado hace más de 1 año
Más
Menos
Creado por
tanitia.dooley
hace más de 11 años
76
1
0
Resumen del Recurso
Atherosclerosis
Atherosclerosis
atheroma-focal disease of the intima-endothelial layer of large & medium sized arteries
risk factors
family history of ischaemic heart disease
modifable risk factors:raised/reduced LDL,hypertension,obesity,physical inactivity,smoking,diabetes mellitus...
stages
1.Endothelial dysfunction (altered PGI2 & NO biosynthesis)
2.Endothelium injury (eg from disturbed blood flow at vessel junctions) leads to monocyte attachment to endothelium
3.Attatched monocytes & ECs generate free radicals, oxidising LDL bound to ECs (lipid peroxidation)
4.Oxidised LDL is taken up by macrophages, which become foam cells. These migrate sub-endothelially to form fatty streaks (precursors of atheroma)
5. SMC hyperplasia (uncontrolled proliferation) & matrix deposition. This leads to a dense fibrous cap overlying a lipid-rich core
6. Rupture leading to a thrombus formation (MI/blood clots)
Lipoprotein Transport
lipid & cholesterol are transported in blood as lipoproteins, 4 main classes: chylomicrons, HDL (exogenous transport), LDL & VLDL (endogenous)
Transport of exogenous lipids
-chylomicrons transport dietary lipids from the gut via lymph & plasma to capillary beds
Core triglycerides are then hydrolysed to free fatty acids by lipoprotein (LP)-lipase
Chylomicron remnants transport cholesterol esters to the liver where they are endocytosed
Released cholesterol is either stored, oxidised to bile acids (secreted in bile) or transported with triglycerides by endogenous transport pathway
Transport of endogenous lipids
Cholesterol & triglycerides transport from liver to the tissues by VLDL
Triglycerides are taken up by the tissues, leading LDL containing cholesterol esters
Cells take up LDL by endocytosis via LDL receptors that recognise LDL apolipoprotein
Cholesterol can return to plasma from tissues in HDL particles
LDL & thombosis
lipoprotein(A) in LDL contains lipids and Apo(A). Apo(A) inhibits plasmin formation, thereby inhibiting fibrinolysis & promoting thrombosis
LDL also activates platelets, further driving thrombosis
Dyslipidaemia
elevated LDL & reduced HDL cholesterol levels cause increased risk of cardiovascular diseases
primary
genetic & classified into 6 phenotypes
eg. type IIa hyper-lipoproteinaemia (LDL receptor defects=increased LDL, dysfunctional thrombosis & increased risk of ischaemic heart disease
Secondary
environment, lifestyle- risk factor for diabetes, renal, thyroid & liver diseases
Lipid lowering drugs
1. Statins
eg Simvastatin, lovostatin, prevastatin
Competitive inhibitors of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis-lower cholesterol syn=increased LDL receptor syn
=increased LDL clearance. MAIN EFFECT IS TO REDUCE LDL-CHOLESTEROL CONCS
Also:improved endothelial function, reduced vascular inflammation, reduced platelet aggregation, increased neovascularization under hypoxia
increased circulating endothelial cell progenitors, plaque stabilisation, reduced atherosclerosis & plaque stabilisation, increased fibrinolysis
Clinical uses-reduce risk of MI & stroke in patients with symptomatic atherosclerosis disease
prevention of arterial disease in patients with high risks
Atorvastatin has long-lasting effects & is used to lower serum cholesterol levels in patients with LDL-R mutations
first line of treatment
2. Fibrates
agonists of nuclear receptor PPARa (activation stimulates lipoprotein lipase production)=increased triglyceride hydrolysis in chlymicrons & VLDL
Plasma triglyceride levels are reduced & FFA are released for storage in fat or for metabolic use in striated muscle
reduce SMC inflammation by inhibiting txn factor NF-kB levels (reduces plasma fibrinogen)
eg. Bezafibrate, ciprofibrate, gemfibrozil, fenofibrate, clofibrate
3. Bile acid resins
anion exhchange resins (colestyramine, colestipol)-sequester bile acids in intestine & prevent their reabsorbtion & recirculation
=decreased absorption of exogenous cholesterol & increased metabolism of endogenous cholesterol into bile acids in liver
=LDL receptor expression on liver increased=further removal of LDL from blood=13% fall in cholesterol levels,20-25% reduction coronary artery disease
side effects- nausea, bloating & diarrhoea
Mostrar resumen completo
Ocultar resumen completo
¿Quieres crear tus propios
Mapas Mentales
gratis
con GoConqr?
Más información
.
Similar
Atherosclerosis and blood clotting
Alice Storr
Smoking and Disease
gordonbrad
Arteries
giorgi.rebecca
PHSI3012 07-1 Pathogenesis of Atherosclerosis
Michael Jardine
Pathophysiology: Immune-Mediated Atherosclerosis
Chadley Kemp
Cardiac Cycle
millie.moo96
Atherosclerosis
Lauren Garner
Capillaries
giorgi.rebecca
Cardiac pathology
Molly Brewster
atherosclerosis
Aminath Maaee
Pathophysiolgy of Atheroclerosis
Jeni Thomas
Explorar la Librería